Predicting outcome in melanoma: where are we now?
Melanoma incidence continues to rise in most countries. This is of grave concern, given the mortality rate in a relatively young population. Current staging tools are limited in their ability to predict accurately those at risk of metastatic disease, relapse and treatment failure. This overview comprehensively reviews relevant literature, with the focus on the last 5 years, and discusses the current state of traditional and emerging novel methods of staging for melanoma and their effect on prognosis in this population.
Jennings
L
L
Department of Dermatology, Beaumont Hospital, Beaumont, Dublin, Ireland. lorrainejenn@gmail.com
Murphy
G M
GM
D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D055088:Early Detection of Cancer / Q000379:methods; D005260:Female; D006801:Humans; D042583:Lymphangiogenesis / Q000502:physiology; D008297:Male; D008545:Melanoma / Q000737:chemistry / Q000145:classification / Q000175:diagnosis*; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods*; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000737:chemistry / Q000145:classification / Q000175:diagnosis*; D014055:Tomography, Emission-Computed / Q000379:methods; D055815:Young Adult
D014408:Biomarkers, Tumor